<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748813</url>
  </required_header>
  <id_info>
    <org_study_id>V71P7S</org_study_id>
    <secondary_id>2008-001079-31</secondary_id>
    <nct_id>NCT00748813</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009</brief_title>
  <official_title>A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Sub</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Annual trial for registration influenza vaccine with the strain composition for season&#xD;
      2008/2009&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) test on Day 0 and on Day 21</measure>
    <time_frame>21 days (-1/+5)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety</measure>
    <time_frame>21 days (-1/+5)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine, Formulation 2008-2009</intervention_name>
    <description>1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects eligible for enrollment into this study are male and female adults who are:&#xD;
&#xD;
               1. â‰¥ 18 years of age, mentally competent, willing and able to give informed consent&#xD;
                  prior to study entry&#xD;
&#xD;
               2. able to comply with all study requirements&#xD;
&#xD;
               3. in good health as determined by:&#xD;
&#xD;
          -  medical history&#xD;
&#xD;
          -  physical examination&#xD;
&#xD;
          -  clinical judgment of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They have any serious chronic or acute disease (in the judgment of the investigator)&#xD;
             including but not limited to:&#xD;
&#xD;
               1. Cancer, except for localized skin cancer;&#xD;
&#xD;
               2. Advanced congestive heart failure;&#xD;
&#xD;
               3. Chronic obstructive pulmonary disease (COPD);&#xD;
&#xD;
               4. Autoimmune disease (including rheumatoid arthritis);&#xD;
&#xD;
               5. Acute or progressive hepatic disease;&#xD;
&#xD;
               6. Acute or progressive renal disease;&#xD;
&#xD;
               7. Severe neurological or psychiatric disorder;&#xD;
&#xD;
               8. Severe asthma.&#xD;
&#xD;
          -  They have history of any anaphylactic reaction and/or serious allergic reaction&#xD;
             following a vaccination, a proven hypersensitivity to any component of the study&#xD;
             vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral&#xD;
             protein, kanamycin and neomycin sulphate);&#xD;
&#xD;
          -  They have a known or suspected (or have a high risk of developing)&#xD;
             impairment/alteration of immune function (excluding that normally associated with&#xD;
             advanced age) resulting, for example, from:&#xD;
&#xD;
          -  receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer&#xD;
             chemotherapy/radiotherapy) within the past 60 days and for the full length of the&#xD;
             study;&#xD;
&#xD;
          -  receipt of immunostimulants;&#xD;
&#xD;
          -  receipt of parenteral immunoglobulin preparation, blood products and/or plasma&#xD;
             derivates within the past 3 months and for the full length of the study;&#xD;
&#xD;
          -  suspected or known HIV infection or HIV-related disease;&#xD;
&#xD;
          -  They have a known or suspected history of drug or alcohol abuse;&#xD;
&#xD;
          -  They have a bleeding diathesis or condition associated with prolonged bleeding time&#xD;
             that in the investigator's opinion would interfere with the safety of the subject;&#xD;
&#xD;
          -  Women who are pregnant, or women able to bear children but not willing to practice&#xD;
             acceptable contraception for the duration of the trial (21 days);&#xD;
&#xD;
          -  Within the past 12 months, they have:&#xD;
&#xD;
          -  received more than one injection of influenza vaccine&#xD;
&#xD;
          -  Within the past 6 months, they have:&#xD;
&#xD;
          -  had laboratory confirmed influenza disease;&#xD;
&#xD;
          -  received influenza vaccine;&#xD;
&#xD;
          -  Within the past 4 weeks they have received:&#xD;
&#xD;
          -  another vaccine;&#xD;
&#xD;
          -  any investigational agent;&#xD;
&#xD;
          -  They have any acute or chronic infection requiring systemic antibiotic treatment or&#xD;
             antiviral therapy within the last 7 days; 1 - They have experienced an acute&#xD;
             exacerbation of a COPD within the past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Lanciano</city>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Pianiga</city>
        <zip>30034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

